Clinical Trials Browser

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Fallopian Tube Neoplasms, Ovarian Neoplasms

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Esophagogastric Cancer

Adenocarcinoma, Neoplasm Metastasis

Lung Cancer - Malignant Pleural Mesothelioma

Esophageal Neoplasms

Sarcoma, Neurofibrosarcoma

Recurrence, Small Cell Lung Carcinoma

Uveal Melanoma

Prostatic Neoplasms

Breast Neoplasms, Breast Neoplasms, Male

Carcinoma, Hepatocellular, Liver Neoplasms

Neoplasms, Small Cell Lung Carcinoma

Neoplasms, Sarcoma

Melanoma, Neoplasm Metastasis

Squamous Cell Carcinoma of Head and Neck

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms, Triple Negative Breast Neoplasms

Rectal Neoplasms

Colonic Neoplasms, Rectal Neoplasms

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Multiple Myeloma

Adenocarcinoma of the Prostate

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Neoplasm Metastasis

Neoplasm Metastasis

Myeloproliferative Disorders, Hematologic Neoplasms

Blast Crisis, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Pancreatic Neoplasms

Clinical Trials

I-SPY

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

EUDARIO

Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer

Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers

MESO-02

Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer

SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)

Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer

STA-9090(Ganetespib) in Metastatic Ocular Melanoma

Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

STA-9090 in Patients With Advanced Hepatocellular Cancer

A Phase I/II Study of Ganetespib in Combination With Doxorubicin

Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas

STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma

Ganetespib Window of Opportunity Study in Head and Neck Cancers

Galaxy 2

A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer

Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer

Clinical and Translational Study of STA-9090

Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer

Enchant

A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma

STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling

A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors

Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors

Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors

STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders

A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia

PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer